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Abstract
Introduction: Test evaluation trials present different challenges for trial managers compared to intervention trials.
There has been very little research on the management of test evaluation trials and how this impacts on trial
success, in comparison with intervention trials. Evaluations of medical tests present specific challenges, because
they are a pivot point bridging the complexities of pathways prompting testing with treatment decision-making.
We systematically explored key differences in the trial design and management of test evaluation trials compared
to intervention trials at the different stages of study design and delivery. We identified challenges in test evaluation
trials that were more pronounced than in intervention trials, based on experience from 10 test evaluation trials.
Methods: We formed a focus group of 7 trial managers and a statistician who had been involved in the day-to-day
management of both test evaluation trials and intervention trials. We used discussion and content analysis to group
challenges from 10 trials into a structured thematic format. The trials covered a range of medical conditions, diagnostic
tests, clinical pathways and conditions including chronic kidney disease, chronic pelvic pain, colitis, detrusor over-
activity, group B streptococcal colonisation, tuberculosis and colorectal, lung, ovarian and thyroid cancers.
Results: We identified 10 common themes underlying challenges that are more pronounced in test evaluation
compared to intervention trials. We illustrate these themes with examples from 10 trials, including with 31 specific
challenges we experienced. The themes were ethics/governance; accessing patient populations; recruitment; patient
preference; test processes, clinical pathways and samples storage; uncertainty of diagnostic results; verifying diagnosis
(reference standard); follow-up; adverse effects; and diagnostic impact.
Conclusion: We present 10 common themes, including 31 challenges, in test evaluation trials that will be helpful to
others designing and managing future test evaluation trials. Proactive identification of potential challenges at the
design and planning stages of test evaluation trials will enable strategies to improve trial design and management that
may be different from standard strategies used for intervention trials. Future work could extend this topic to include
challenges for other trial stakeholders including participants, clinicians, statisticians and funders.
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Background
Test evaluation trials present different challenges for trial
managers compared to intervention trials. Clinical trials are
the highest standard of evidence for new treatments and in-
terventions and require a significant investment in time
and money. Despite this, many trials fail to recruit to target
or complete recruitment /follow-up in line with the proto-
col [1–3]. This failure delays the implementation of effect-
ive treatments and may produce sub-optimal data sets that
are too small to reliably answer the question posed.
There has been a great deal of research into clinical
trial conduct and completion which has focussed on
many aspects of trial design, site selection and monitor-
ing, participant recruitment and retention [4–6]. The
UK National Institute Health Research (NIHR) and
Medical Research Council (MRC) have invested in meth-
odologies to improve trial design and management, par-
ticularly recruitment and retention including the MRC
START, ORRCA and Trials Forge initiatives [7–9], and
encourage studies within trials to address these issues.
However, this work has mostly focussed on intervention
trials and may not be as relevant for other trial designs.
In recent years, there has been an increase in the num-
bers of test evaluation trials, trials that assess how cor-
rectly a test detects the presence or absence of a target
condition. This article discusses test evaluation trials
conducted in a clinical trials unit, distinguishing these
from test evaluation studies which may have a less strict
protocol-directed design, data collection and analysis
methods. Trials can evaluate tests in the context of diag-
nosis, screening, monitoring, impact on therapeutic
management, as prognostic tests or by directly measur-
ing patient outcomes. Diagnostic trials can evaluate the
accuracy, time to diagnosis, diagnostic yield, number of
tests in a patient pathway or other diagnostic outcomes.
These diagnostic evaluation trials fundamentally differ
from intervention trials in the relationship to partici-
pants, uncertainty for participants and how these trials
affect patient care pathways. Designs of diagnostic trials
differ reflecting the different trial objectives. For ex-
ample, for many test evaluation trials, a randomised de-
sign is not the best or most efficient design, exemplified
by trials comparing diagnostic tests where participants
may receive all the tests being compared as well as a ref-
erence standard test. In some trials of new tests where
the accuracy is not established in clinical practice, the
trial will be designed so the new test results are not re-
vealed during patient care to prevent an unproven test
influencing patient treatment.
There is a clear need for specific guidance on the de-
sign and management of test evaluation trials, identified
by differences in the role of study designs, study biases,
systematic review guidelines and reporting guidelines for
these trials [10–14]. The current literature has focussed
on important aspects of design including phases of design
and statistical methods [15–17]. Our paper by contrast
aims to provide a handy summary of past experience
aimed primarily for trial managers to help planning of the
practical aspects of diagnostic evaluation trials.
We identified challenges in test evaluation trials that
were more pronounced than in intervention trials, using a
focus group of trial managers and a statistician, based on
our experience of 10 trials managed at Birmingham Clin-
ical Trials Unit (BCTU) or in collaboration with the Test
Evaluation Group at the University of Birmingham. Our
paper presents 10 themes, mainly aimed at trial managers,
to prompt discussion of practical challenges that can arise
in a diagnostic evaluation trial. Early recognition of these
issues can greatly aid trial management.
Methods
We explored the views and opinions of a face-to-face focus
group at BCTU consisting of 9 individuals including trial
managers who had managed both intervention trials and
test evaluation trials and senior statisticians experienced in
test evaluation trials. We used content analysis to systemat-
ically organise our experience of challenges into a structured
format. We circulated a plan, including test evaluation trials
proposed for inclusion and preliminary identification of dif-
ferent areas of trial management to discuss. Our focus
group met face to face four times in a BCTU meeting room.
We included all the diagnostic trials on which members of
the focus group were currently directly working on as either
trial managers or statisticians. In the first meeting, we
reflected on the challenges in test evaluation trials which
were different from intervention trials, and in turn, each
member reflected on the most challenging issues in their tri-
als. Based on the challenges identified, we started to develop
themes to systematically group our experiences which were
refined over subsequent meetings. Over the following three
meetings of 1-h duration (Feb to April 2017), we focused on
3 or 4 themes per meeting, systematically asking focus
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group members for each trial in turn to identify challenges
for the themes. Discussion in the group and examples from
other trials often elicited other examples, as common
themes were identified between trials. After each meeting,
notes were circulated to the focus group for feedback. Cha-
llenges were grouped into a list of 10 areas of trial manage-
ment, and examples from different trials were selected to
illustrate issues in each area by two members of the focus
group and circulated to the full focus group for feedback.
All members of the focus group were invited to participate
in authorship or to be acknowledged. Results were cir-
culated to trial chief investigators for feedback. We used the
Consolidated Criteria for Reporting Qualitative Studies
Checklist (COREQ) [18] to guide the reporting.
Results
The group consisted of 7 trial managers and a statisti-
cian who had a range of experience in the design, man-
agement and oversight of trials based on the number of
diagnostic trials, time and timing of their involvement
(pre-, during or post-recruitment phases). Most mem-
bers of the group had experience in both intervention
trials and test evaluation trials. At least one group mem-
ber had participated in the management-related issues
for the 10 trials considered (see Table 1) that had been
managed at BCTU, or in collaboration with the Test
Evaluation Group at the University of Birmingham.
Ethics/governance
In some test evaluation trials, the timing of providing a
patient information sheet to participants for trial recruit-
ment is sensitive. This is because sometimes when tests
are ordered, participants have not had a discussion with
clinical staff about the full range of conditions that tests
are designed to detect or rule out. This complicates
much of the documentation given to participants, from
the title of the project to explanations in the patient in-
formation sheet (PIS).
In some test evaluation trials, test results are not re-
vealed to participants or clinicians in the patient care
pathway. Where test results will not be made available
in a time frame to benefit the patient, the potential lack
of benefit to trial participants needs to be clear and may
discourage participation. When the performance of the
test is not sufficiently established to use in clinical prac-
tice, it is important results are not revealed to protect
participants from potential harm. Where trials are de-
signed to collect patient samples to develop and evaluate
new tests, explaining the purpose of the trial can be
harder as the trial may not list all tests that will be
Table 1 Test evaluation trials
Trial title Funder Registration number
BUS - Accuracy of Bladder Ultrasound (BUS) in the diagnosis of Detrusor Overactivity (DO): a
study to evaluate if ultrasound can reduce the need for urodynamics [18].
NIHR
HTA
BUS: ISRCTN:46820623. Registered on
September 18, 2012
eGFR-C - Accuracy of glomerular filtration rate (GFR) estimation using creatinine and cystatin C




eGFR-C: ISRCTN: 42955626. Registered
on October 08, 2013
ElaTION - The Efficacy and Cost effectiveness of Real Time Ultrasound Elastography in The
Investigation Of Thyroid Nodules and the diagnosis of thyroid cancer.
NIHR ElaTION: ISRCTN:18261857. Registered
on January 28, 2015
ENDCaP-C - Enhanced Neoplasia Detection and Cancer Prevention in Chronic Colitis: a




on May 11, 2015
GBS-2 - Accuracy of a rapid intrapartum test for maternal group B streptococcal colonisation and
its potential to reduce antibiotic usage in mothers with risk factors.
NIHR GBS-2: ISRCTN:74746075. Registered on
April 16, 2015
MEDAL - Can magnetic resonance imaging scan replace or triage the use of laparoscopy in




MEDAL: ISRCTN:13028601. Registered on
February 20, 2012
IDEA - An observational cohort study to evaluate the clinical utility of current and second-
generation interferon-gamma release-assays in diagnostic evaluation of tuberculosis [16, 17]a
NIHR
HTA
IDEA - Not registered
METRIC - Diagnostic accuracy for the extent and activity of newly diagnosed and relapsed Crohn




METRIC: ISRCTN:03982913. Registered on
November 5, 2013
ROCkeTS – Refining Ovarian Cancer Diagnostic Test Accuracy Scores [23]. NIHR
HTA
ROCkeTS: ISRCTN:17160843. Registered
on June 3, 2015
STREAMLINE-COLON, STREAMLINE-LUNG. Diagnostic accuracy for metastatic disease in newly
diagnosed lung and colorectal cancer: Prospective comparison of whole-body magnetic reson-




Registered on August 28, 2015
aManaged by Hilary S Whitworth with input from J Deeks
bManaged by the University College London Clinical Trials Unit, London; senior statistician SM
cManaged by the Cancer Research UK & UCL Cancer Trials Centre, London; senior statistician SM
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conducted on patient samples, to enable future proofing
if a future new biomarker is discovered.
In some trials, ethical concerns mean that test results
may need to be revealed to participants during their
treatment pathway.
Example 1: Impact of trial title
ROCkeTS (Refining Ovarian Cancer Test Accuracy
Scores) recruits women with suspicion of ovarian cancer
immediately on contact with secondary care. We wanted
to send the patient information sheets (PIS) with the
clinic appointment letter, to give participants more time
to consider joining the trial. As clinicians had not neces-
sarily used the word “cancer” as a potential reason for
the referral, there were concerns about causing alarm,
and clinicians in some cases refused to send out PIS
ahead of the clinic appointment.
Similar issues were also identified in eGFR-C, Ela-
TION and STREAMLINE. In STREAMLINE, the PIS
clearly stated that the patient may not have cancer in
the permissions for the extra trial MRI.
Example 2: Uncertainty in project pathway
ROCkeTS aims to externally validate the existing tests
and risk scores and develop a new risk score on the trial
cohort of participants. As the project allowed for a po-
tential change in the tests to be performed on the serum
samples, it was harder to explain to participants the pur-
pose of the test evaluation study than an intervention
study comparing two treatments.
Example 3: Trial test result availability for patient care
In STREAMLINE, whole-body MRI was being evaluated
in comparison with standard pathways to detect the
presence of metastases at cancer diagnosis. Results from
whole-body MRI were made available for patient care,
because MRI is an accepted test for the detection of me-
tastases, and all participants received MRI in addition to
standard care.
Accessing patient population or accessing participants
Accessing the patient population in test accuracy trials
poses different issues to intervention trials, as partici-
pants need to reflect the appropriate balance of the rele-
vant clinical population to allow accurate evaluation of
the test at the relevant point in the patient pathway.
Typical issues include clinician bias, screening burden
and time constraints, requirement for clinician referral
and access to participants at a relevant point in the pa-
tient pathway.
Example 1: Screening burden
In ENDCaP-C, recruitment relied on screening endos-
copy lists, where the information was not in a readily
accessible format and only a minority of patients are po-
tentially eligible. Some trials may require screening of
every available patient, which can amount to thousands
of potential participants. In eGFR-C for example, 30,000
patients were screened or approached to recruit 1200.
Example 2: Clinician referral required
In ElaTION, radiologists were not able to arrange the
requisite repeat appointments directly, leading to com-
munication issues with non-ElaTION referring consul-
tants to follow the correct trial pathway. In STREAMLI
NE, whole-body MRI is compared to NICE pathways as
a cancer staging test, requiring referral to another hos-
pital at some centres. This raises concerns that older pa-
tients and patients who are temporarily ill at the time of
cancer diagnosis could be less likely to be tested due to
burden and perceived benefit, potentially restricting the
range of the included population.
Example 3: Access to population
In ROCKeTS, the ultimate goal is to use the test in pri-
mary care to improve the accurate triaging of women re-
ferred to secondary care. Unfortunately, it is only
feasible to recruit in secondary care at the point of refer-
ral, because of the low prevalence of ovarian cancer in
patients seen by GPs. Recruiting of women at referral to
secondary care needs to take into account that hospital re-
ferrals include women referred from both primary care
and other secondary care disciplines. In addition, the re-
ferral population varies between secondary or tertiary care
hospitals, complicating the screening of participants.
Recruitment
To ensure that the relevant clinical population is used to
evaluate a test, recruiting a consecutive series or repre-
sentative (unselected) population of eligible participants
is the ideal. Further complexities result because recruit-
ment often requires collaboration between specialist dis-
ease clinical staff and general clinical teams not invested
in the trial such as radiologists and pathologists. Varia-
tions in the diagnostic pathway between hospitals can
also require an understanding of local pathways for
recruitment.
Example 1: Spectrum bias
In IDEA, adults presenting with suspected active tuber-
culosis (TB) to NHS outpatient or inpatient services
were included. However, due to an error in the imple-
mentation of recruitment criteria at one site, only pa-
tients with confirmed or highly probable TB were
recruited. These participants were excluded from the
trial analysis [19, 20].
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Example 2: Complex pathways
In ElaTION, eligible patients were often not approached
because they had been referred from primary care where
it is the responsibility of the GP to review the radiology
report and decide on the next action. Trial staff needed
to create their own clinic list in order to recruit patients.
In ROCkeTS, women are eligible based on ultrasound
scan and/or abnormal CA125 test results in combination
with symptoms. Different hospitals organise ultrasound
scanning in different ways, some as a one-stop shop for
women with symptoms of ovarian cancer, whereas other
hospitals have a general ultrasound service for all re-
ferred patients regardless of the referral reason. This af-
fects whether consecutive recruitment is feasible.
Example 3: Incompatible pathways
In eGFR-C, eligibility was confirmed by a repeated kid-
ney function test within a given time interval which was
expected to be met by the advised routine practice.
However, as the test was often not repeated in real-
world clinical practice, many potentially eligible patients
did not meet the criteria.
Patient preferences
The burden on participants and the invasiveness of test-
ing during diagnostic trials can mean that not all partici-
pants complete all scheduled tests. A fuller assessment
of patients’ preferences and issues during diagnostic tri-
als involving patients would be important for future
research.
Example 1: Research burden
In STREAMLINE, efficient recruitment for whole-body
MRI requires pre-reserved slots on MRI, so standard
NHS services are not affected by research trials. For
some participants, the burden of travelling to a different
hospital for a specialised MRI may have affected recruit-
ment. In eGFR-C, the burden of a 3-year follow-up re-
quired for the reference test discouraged some
participants from completing the study.
Example 2: Invasiveness of testing
In ENDCaP-C, a second invasive colonoscopy test may
be required solely for trial purposes, which led to chal-
lenging management and participant loss to follow-up.
Test processes, clinical pathways and sample storage
In test evaluation trials, pathways are often complex in-
volving multiple teams which can create logistical bar-
riers to recruitment, completing clinical contact and also
in patient follow-up. While the group agreed that many
of these barriers also occurred in intervention trials, they
felt that they were particularly challenging in a test
evaluation setting where participants were undergoing
additional tests solely for research purposes.
Test evaluation trials routinely produce a combination
of data and accompanying test samples, e.g. tissue,
blood, images, which are also a valuable resource for fu-
ture research. Curating and futureproofing these collec-
tions are an important part of the design and may lead
to data being collected with a view to future use rather
than the immediate project. In the immediate project,
standardisation can be required in imaging tests for the
format of image collection, machine resolution, anon-
ymization and measurements made during imaging. This
standardisation may be to stricter standards than will be
done in routine practice which may affect how the test
performs in the real world.
Example 1: Specialised staff training for test
In ROCkeTS, at some sites, only a sub-set of sonogra-
phers was trained to perform one of the tests, and
adjusting the normal appointment process to ensure that
trial participants were referred to specific sonographers
was challenging.
Example 2: Preparation and handling of tissue samples
In ROCkeTS, samples are tested in batches on a single
platform, and given the number of tests, new sets of
reagents will be used; this is unlikely to reflect normal prac-
tice where samples are run on an ad hoc basis. Similarly, in
eGFR-C, all samples are tested at one of two central labora-
tories rather than in local hospital laboratories.
Example 3: Specialised test processes
In STREAMLINE, whole-body MRI was part of one
diagnostic pathway identifying cancer metastasis. The
trial protocol specified a minimum of image sequences,
but the local hospital decided on the MRI platform
(manufacturer and Tesla strength) and imaging parame-
ters. To maintain blinding of MRI images and interpret-
ation to the standard diagnostic pathway, software was
installed to upload the MRI images to provide a secure
data upload to a secure central imaging server. MRI im-
ages were downloaded to the local hospital PACS sys-
tems after relevant trial reports were completed.
Example 4: Logistics
In IDEA, blood samples to be tested using interferon
gamma release assays for active TB required laboratory
processing within 8 h. Rapid transport was needed to la-
boratories in London, Leicester and Birmingham and
meant that participants could only be recruited from
morning clinics only as the laboratory was not open 24 h.
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Uncertainty of test results
Clinicians can feel that they are being tested personally ra-
ther than that the trial is measuring current standard prac-
tice, making trial participation and completeness of trial
data more challenging. This is more frequent when the trial
includes tests requiring interpretation by clinicians where
test interpretation is more subjective involving skilled clin-
ical interpretation such as in imaging tests. Reference tests
based on consensus panel decisions and trials measuring
the diagnostic impact of a test can also make clinicians feel
their personal skills are being assessed.
In laboratory tests, uncertainty in test results can be
caused by changes in measurement methods in trials
with a long follow-up. This can affect tests and reference
standards and may require careful consideration.
Example 1: Current standard practice vs individual clinician
performance
Clinicians feeling their personal skills are being assessed
can result in incomplete reporting of data. This can
occur in imaging trials and where clinicians are asked to
give their opinion or a diagnosis based on the reference
standard or incomplete data. This has led to incomplete
data being returned, an issue identified in MEDAL, Ela-
TION and ROCkeTS.
Verifying diagnosis (reference standard)
In test evaluation trials, a reference standard is used to
establish a “true” diagnosis, and all other tests are com-
pared using this “true” diagnosis. The accuracy of the
reference standard to correctly identify the target condi-
tion impacts how the test being evaluated appears to
perform. The reference standard may be another test
such as histology or a combination of tests or a consen-
sus panel interpretation of tests.
Example 1: Consensus panel reference standard
In MEDAL, the reference standard is the decision of a
panel of experts who, despite decision rules, may disagree.
Differences in specialist training in combination with how
information was presented to the consensus panel may
have led to differences in panel member decisions.
Example 2: Reference standard tests can include different
tests in different participants
In METRIC, additional tests were required in some par-
ticipants where test results disagreed on the presence or
location of the disease. In some participants, an add-
itional test was required to resolve disagreements be-
tween tests contributing to the reference standard.
Example 3: Availability of reference standard
In GBS, an enriched method of bacterial culture is the
reference standard. However, not all sites do this test
routinely, resulting in concerns about the need to train
microbiologists to interpret the results.
Follow-up
Follow-up can be particularly challenging in test evalu-
ation trials. Participants may be less willing to return for
further “unnecessary” appointments or tests that are part
of the trial but not part of the normal clinical pathway.
Clinicians may be less willing to refer participants for
further trial follow-up if this does not reflect the clinical
pathway, particularly where participants with negative
tests may in normal practice be discharged from clinic
follow-up.
Follow-up of participants can be important for dif-
ferent aspects of the trial, depending on the trial ob-
jective. For example, in diagnostic accuracy and
prognostic studies, follow-up can be part of the refer-
ence standard, whereas economic modelling may re-
quire follow-up QoL data. In diagnostic impact trials
and monitoring trials, follow-up can be necessary to
identify how subsequent testing, patient management
and outcomes change.
Example 1: Change in current practice
In ElaTION, during the trial, clinical guidelines changed to
remove a second patient scan that was important for the
trial resulting in a drop in referrals. Similarly, the trial GBS
may be affected by a change in clinical guidelines. In both
instances, these tests formed part of the trial follow-up.
Example 2: Referrals
In ElaTION, consultants can decide whether to refer for
the repeat test or not which may selectively affect
follow-up of participants with a benign disease that con-
tributes to the reference standard.
Example 3: Contact with patient
In ENDCaP-C, participants follow different pathways de-
pending on methylation and histology results, so patient
follow-up is different for different participants and it is
difficult to confirm follow-up visits with participants and
trialists until the test results are completed.
Adverse effects or harms
Adverse effects (AEs) may be less important in test
evaluation trials as if the study is investigating tests used
in usual care, AEs directly attributable to standard tests
are unusual. However, in a complete diagnostic pathway
including treatment, it can be confusing to know how
far along the pathway AEs are attributable to tests. In
addition, in some situations, AEs caused by testing might
be considered important to address.
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Table 2 Differing themes and challenges from diagnostic test accuracy trials
Themes Challenges Description
Ethics/governance Patients approached for recruitment require information
that is sensitive to their knowledge of their disease.
Timing is sensitive as information may need prior discussion
with the participant about what condition tests are designed to
detect or rule out. This requires careful consideration of the trial
title and the patient information sheet.
Explaining the purpose of the trial, where trial design
collects patient samples to evaluate and develop new
tests.
Explaining the purpose of the trial to patients can be more
complicated where the trial does not list all tests based on
patient samples.
Explaining the purpose of trial developing a new test may
lead to questions about deficiencies in the current test
pathway.
Explaining the purpose of trial evaluating current tests or
developing a new test can be complicated, as it may raise
questions about the current diagnostic pathway, its accuracy
and uncertainties.
No direct benefit to participants. Trial may be about developing a new test, so trial participants
have on direct benefit.
Trial test results availability required for patient care where
appropriate.
For ethical reasons, test results may need to be revealed for




Screening burden. Eligible patients may need to be screened manually from the
hospital clinic list where the clinic conducts a test used to
diagnose several diseases, but the trial only relates on one type
of referral.
Accessing patients at a clinically relevant time point. Hospital clinics receive patients through different referral
pathways, only some of which may be relevant to the trial.
Hospitals arrange clinical care pathways differently.
Recruitment Patients eligible for the trial should represent a clinical
referral population without clinical selection (spectrum
bias)
Requirement for an additional clinician referral required by the
trial can affect who gets recruited.
Clinicians can misunderstand eligibility criteria and select
participants by referral plus their clinical suspicion.
Recruitment requires collaboration between specialist
disease and general clinical teams
Patient recruitment may occur in the radiology department for
trial diagnosing a specific disease requiring recruitment in
clinics without research staff directly involved in the trial.
Collaboration across clinical settings Patient pathway in the hospital may depend on the
interpretation of tests made by primary care clinicians.
Patient preferences Research burden. Participants may find it difficult to attend additional hospital
appointments or travelling to a different hospital site when they
are feeling ill, or it takes extra time from family care or work.
Reference test may be too onerous to patients. For some participants, follow-up may require an additional inva-




Trial may require a change in clinic patient pathway or
referral to specialist test clinic.
Trial pathway may require referral to staff trained in a new test
method.
Test may not be available in a recruiting centre but may take
place at a specialist hospital clinic.
An extra test or patient sample is required for trial. Different clinics may need to order or interpret the test,
resulting in delays or reduced recruitment.
Test may require extra staff training to conduct or interpret
test results.
Can restrict recruitment to time periods when staff with
specialist test training are on duty.
Extra staff training may be required.
Trial includes standardisation of test processes to a higher
standard than normal clinical practice.
Tests may require additional burden on clinics of specialist
equipment or calibration of equipment or additional software
or extra clinical interpretation.
Patient sample may need immediate testing by a specialist
laboratory.
Recruitment sites had to be within a certain distance of
laboratory to enable sample testing within a required time.
Requires additional requirements for collection and
storage of trial samples, in addition to normal clinical
practice.
Additional burden to clinics including anonymisation of images,
cloud/server storage of images, sending samples, collation of
patient information for interpretation at a second site, etc.
Trial may store samples of blood or tissue for future test
development.
Requires curation and future proofing tissue storage.
Uncertainty of test
results
In tests requiring interpretation by clinicians, clinicians can
feel their ability is being tested, rather than the test.
Clinicians may be cautious or report some data intermittently if
they feel the trial is measuring their performance rather than
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Example 1: Definition of AEs
In ElaTION, AEs can occur during surgery, but partici-
pants in both RCT arms have surgery, so it was harder
for nurses to understand which AEs should be recorded
as directly attributable to the tests and which are
assigned to trial treatments.
Example 2: Minimising irrelevant AEs
In eGFR-C, AEs are time-limited to 24 h from the test to
ensure they are attributable to the test (use of a contrast
medium) as most of the 1200 participants are elderly
and followed up over 3 years.
Example 3: Understanding harm caused by the process of
testing
In ROCkeTS, there is a questionnaire capturing
stress caused by testing for cancer as a possible con-
dition accounting for symptoms and prior test
results.
Diagnostic impact
The impact of the test can be hard to separate from
other parts of the clinical pathway or model. Incre-
mental changes in test accuracy may improve a test
but not be sufficient to change practice.
Table 2 Differing themes and challenges from diagnostic test accuracy trials (Continued)
Themes Challenges Description
the performance of the test in a typical clinical setting.
Calibration of the index and reference tests across time
can be problematic.
Calibration and standardisation of tests and equipment over
time can affect diagnostic performance.
Verifying diagnosis
(reference standard)
Reference standard may require formation of an expert
consensus group to review and interpret patient diagnosis
based on several tests.
Requires extra time from staff and clinicians to prepare and
attend meetings.
Processes to resolve disagreements are needed.
Reference test may depend on the results from the index
tests.
Additional tests may be required when index tests disagree.
Reference test requires a specialist test. If a specialist test is required as part of the reference test, it may
not be available at all hospital sites and may require specialist
training.
Follow-up Patient follow-up is often needed to confirm disease
status.
Participants may be unwilling to return for “unnecessary”
appointments.
Clinicians may be unwilling to refer participants for additional
follow-up tests not part of usual clinical practice.
Clinical guidelines can change and affect tests forming part of
trial follow-up.
Follow-up tests and procedures can be different for
participants, depending on their test results during the
trial.
Follow-up for a patient can vary from further imaging, surgery,
histology of sample from surgery to follow-up of primary care
records.
Follow-up may require collaboration across clinics or
healthcare settings.
Follow-up in participants with no disease may require follow-up
through primary care, patient contact or national databases.
Adverse effects or
harms
Can be difficult for clinical staff to understand which AE in
the clinical pathway should be recorded as relevant to the
trial.
Discussion of AE relevant to the trial needs careful definition
differentiating AE from the test itself or AE in patient pathway
alternation by use of the test.
AE can be caused by consenting a patient for testing
within a trial.
Informed consent may make participants more aware of the
range of diagnoses from tests than discussed in clinical practice.
Trial participation may also prompt more discussion about
diagnostic uncertainty from current tests.
Diagnostic impact Measuring the impact of tests on patient management. Patient management decisions can be captured within
diagnostic accuracy trials. The highest level of evidence is from
an RCT of using tests as an intervention, but alternative designs
reporting patient management decisions instead of patient
outcomes can, for some tests, provide important evidence on
test impact faster and at a lower cost.
Understanding the incremental benefit of a particular test
within a complex patient pathway is difficult.
Separating a test to measure its individual impact can become
artificial.
Understanding what difference in diagnostic accuracy or
diagnostic confidence is required to change clinical
practice.
Often adding a test into a test pathway has an incremental
value on certainty or timing of diagnosis.
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Example 1: Measuring impact on patient management
STREAMLINE compares patient management decisions
made on the basis of different test pathways during clin-
ical multi-disciplinary meetings for cancer patients. Cap-
turing patient management decisions in a diagnostic trial
is a newer design that is cheaper and faster than com-
pleting an RCT using a test as an intervention, but is
likely to include more potential bias from difficulties in
blinding and reporting decisions made in real time in
the patient pathway.
Example 2: Separating test from complex pathway
In MEDAL, the incremental add-on value of individual
components from a complex pathway was assessed using
scenarios from trial participants assessed offline from
the real patient treatment decisions. Asking clinicians to
evaluate the impact of using a test in a theoretical sce-
nario may not be realistic and could inflate the impact
of the test in decision-making.
Example 3: Implementation
In ROCkeTS, the impact of a new test will depend on
GP confidence to change the patient pathway and stop
referring patients to secondary care. There is no evi-
dence on the thresholds in diagnostic accuracy that a
test would have to perform at to change practice.
Discussion
We identified 10 common themes underlying the chal-
lenges that are more pronounced and in some instances
unique in test evaluation compared to intervention trials
(Table 2). We illustrate these themes with examples
from 10 trials, including with 31 specific challenges we
experienced. Some themes were expected such as for
reference standards, but others such as challenges acces-
sing patient populations were unanticipated. In most
cases, the realisation of these challenges earlier in the
trial would have greatly aided trial management.
Design and management of test evaluation trials
clearly pose different challenges to intervention trials.
Recognition of specialist skills needed and training for
CTUs in design and management of test evaluation trials
will be important to increase success. Having a clear un-
derstanding of these specialist challenges allows strat-
egies to address them to be incorporated into the project
management plan to improve the trial delivery. These
strategies may well start at the grant application stage
and influence many aspects of the design and manage-
ment. As with intervention trials, the effectiveness of the
strategies needs to be reviewed on an ongoing basis dur-
ing the lifecycle of the trial.
This project focus group considered 10 test accuracy
trials across a range of diseases managed at BCTU or
analysed within the Test Evaluation Group at the Uni-
versity of Birmingham. Including 10 trials and 8 trialists
was a limitation of our study; a broader range of trials or
opinions from trial managers at other trials units may
have identified additional issues. The current literature
on trial management focusses on interventional trials
and we are not aware of other studies providing this
practical trial management experience for diagnostic ac-
curacy trials to aid future trials and trialists. This paper
focused on trial management and did not aim to include
all issues in test evaluation trials relevant to clinicians,
research nurses, patients, statisticians and other stake-
holders. There clearly is the need for a larger project on
this topic including these other perspectives.
This paper provides important insight into improving
the design and delivery of clinical trials in test evalu-
ation, as well as identifying the need for further work.
Conclusion
Test evaluation trials are fundamental to the improving
diagnosis of disease and decision-making for efficient
and effective patient treatment pathways. Ensuring the
quality of data and the clinical relevance of the recruited
participants are dependent on trial design and manage-
ment practices that are tailored specifically to test evalu-
ation trials.
We provide a list of 10 themes, including 31 chal-
lenges, to prompt discussion of practical challenges that
can arise in a diagnostic evaluation trial. Early recogni-
tion of these issues can greatly aid the design and man-
agement of future test evaluation trials.
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